12:00 AM
 | 
Aug 09, 2010
 |  BC Week In Review  |  Company News  |  Other News

Cypress, Forest Laboratories musculoskeletal, neurology news

Cypress will restructure and reduce headcount by 123 (86%) to 20 after it discontinued co-promotion of fibromyalgia drug Savella milnacipran in the U.S. with partner Forest. The cuts come from the company's commercial business. Cypress, which remains eligible for royalties on Savella, said it "may pursue the opportunity to re-activate the co-promotion right." Cypress will receive a one-time payment from Forest of $2...

Read the full 301 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >